Antivirals for monkeypox virus: Proposing an effective machine/deep learning framework

Author:

Hashemi Morteza,Zabihian Arash,Hajsaeedi Masih,Hooshmand MohsenORCID

Abstract

Monkeypox (MPXV) is one of the infectious viruses which caused morbidity and mortality problems in these years. Despite its danger to public health, there is no approved drug to stand and handle MPXV. On the other hand, drug repurposing is a promising screening method for the low-cost introduction of approved drugs for emerging diseases and viruses which utilizes computational methods. Therefore, drug repurposing is a promising approach to suggesting approved drugs for the MPXV. This paper proposes a computational framework for MPXV antiviral prediction. To do this, we have generated a new virus-antiviral dataset. Moreover, we applied several machine learning and one deep learning method for virus-antiviral prediction. The suggested drugs by the learning methods have been investigated using docking studies. The target protein structure is modeled using homology modeling and, then, refined and validated. To the best of our knowledge, this work is the first work to study deep learning methods for the prediction of MPXV antivirals. The screening results confirm that Tilorone, Valacyclovir, Ribavirin, Favipiravir, and Baloxavir marboxil are effective drugs for MPXV treatment.

Funder

Iran National Science Foundation

Publisher

Public Library of Science (PLoS)

Reference45 articles.

1. Mpox (monkeypox): Diagnosis, prevention, and management in adults;L Jarrell;The Nurse Practitioner,2023

2. Mini Review on Clinical Aspects of Monkeypox;Y Saraswat;Current Pharmaceutical Biotechnology,2024

3. Correlation between monkeypox viral load and infectious virus in clinical specimens;CK Lim;Journal of Clinical Virology,2023

4. cdc. 2022 U.S. Map & Case Count | Mpox | Poxvirus | CDC—cdc.gov; 2024. https://www.cdc.gov/poxvirus/mpox/response/2022/us-map.html.

5. Clinical use of tecovirimat (Tpoxx) for treatment of monkeypox under an investigational new drug protocol—United States, May–August 2022;K O’Laughlin;Morbidity and Mortality Weekly Report,2022

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3